ARCH Venture Fund X, L.P. - Mar 31, 2025 SCHEDULE 13G Report for Maze Therapeutics, Inc. Common Stock par value $0.0001 per share (MAZE)

Filing Manager
ARCH Venture Fund X, L.P.
Reporting Manager
ARCH Venture Fund X, L.P.
Security
Maze Therapeutics, Inc. Common Stock par value $0.0001 per share
Symbol
MAZE
Shares outstanding
43.8M shares
Disclosed Ownership
4.12M shares
Ownership
9.4%
Form type
SCHEDULE 13G
Date filed
5/15/2025, 05:05 PM
Date of event
Mar 31, 2025
SEC
View on sec.gov

Reporting Managers (9)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
ARCH Venture Fund X, L.P. 9.4% 4.12M 0 4.12M ARCH Venture Partners X, L.P. its General Partner
ARCH Venture Fund X Overage, L.P. 9.4% 4.12M 0 4.12M ARCH Venture Partners X Overage, L.P. its General Partner
ARCH Venture Partners X, L.P. 9.4% 4.12M 0 4.12M ARCH Venture Partners X, LLC its General Partner
ARCH Venture Partners X Overage, L.P. 9.4% 4.12M 0 4.12M ARCH Venture Partners X, LLC its General Partner
ARCH Venture Partners X, LLC 9.4% 4.12M 0 4.12M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director
Keith Crandell 9.4% 4.12M 0 4.12M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Keith Crandell
Kristina Burow 9.4% 4.12M 0 4.12M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Kristina Burow
Steven Gillis 9.4% 4.12M 0 4.12M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Steven Gillis
Robert Nelsen 9.4% 4.12M 0 4.12M /s/ Mark McDonnell * Mark McDonnell, as Attorney-in-Fact for Robert Nelsen